What is HC Wainwright’s Forecast for ACRS FY2025 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research note issued to investors on Sunday, November 9th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn ($0.50) per share for the year, up from their prior forecast of ($0.51). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.53) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. Aclaris Therapeutics had a negative return on equity of 34.01% and a negative net margin of 802.03%.The company had revenue of $3.30 million for the quarter, compared to analysts’ expectations of $1.59 million.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Aclaris Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $8.71.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $2.41 on Wednesday. Aclaris Therapeutics has a 1 year low of $1.05 and a 1 year high of $5.17. The firm’s 50 day moving average price is $2.07 and its 200-day moving average price is $1.72. The stock has a market cap of $261.11 million, a P/E ratio of -1.76 and a beta of 0.43.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers increased its holdings in shares of Aclaris Therapeutics by 7.4% in the 3rd quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock worth $173,000 after buying an additional 6,271 shares during the last quarter. AXQ Capital LP purchased a new position in Aclaris Therapeutics in the third quarter worth about $27,000. CRA Financial Services LLC bought a new stake in Aclaris Therapeutics during the second quarter worth approximately $25,000. ProShare Advisors LLC purchased a new stake in Aclaris Therapeutics during the second quarter valued at approximately $26,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Aclaris Therapeutics during the second quarter valued at approximately $28,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.